Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Dermatologic 1

Conditions

Hodgkin Disease 20Lymphoma 6Lymphoma, T-Cell, Peripheral 5Lymphoma, T-Cell 5Mycosis Fungoides 4Lymphoma, T-Cell, Cutaneous 4Lymphomatoid Papulosis 3Lymphoma, Large-Cell, Anaplastic 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Lymphoma, Primary Cutaneous Anaplastic Large Cell 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Immunoblastic Lymphadenopathy 2Hematologic Diseases 2Enteropathy-Associated T-Cell Lymphoma 2Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Mesothelioma, Malignant 1Melanoma 1Lymphoma, Extranodal NK-T-Cell 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Large Granular Lymphocytic 1Leukemia 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 244Carboplatin 213Pemetrexed 179Cisplatin 133Paclitaxel 115Nivolumab 102Docetaxel 88osimertinib 84durvalumab 79Specimen Handling 56atezolizumab 55Gemcitabine 53Drug Therapy 53Magnetic Resonance Spectroscopy 50Radiosurgery 49Radiotherapy 48Ipilimumab 41130-nm albumin-bound paclitaxel 39cemiplimab 38Bevacizumab 35tislelizumab 31Cetuximab 30amivantamab 23Taxes 22Blood Specimen Collection 21Platinum Compounds 20Immunotherapy 18Immune Checkpoint Inhibitors 18Radiation 17Erlotinib Hydrochloride 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × Brentuximab Vedotin × 1 year × Clear all
NCT04609566 2026-03-16

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Seagen Inc.

Phase 2 Completed
161 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡